WO2003041656A3 - Soluble drug extended release system - Google Patents

Soluble drug extended release system Download PDF

Info

Publication number
WO2003041656A3
WO2003041656A3 PCT/US2002/036681 US0236681W WO03041656A3 WO 2003041656 A3 WO2003041656 A3 WO 2003041656A3 US 0236681 W US0236681 W US 0236681W WO 03041656 A3 WO03041656 A3 WO 03041656A3
Authority
WO
WIPO (PCT)
Prior art keywords
soluble drug
extended release
release system
drug
novel
Prior art date
Application number
PCT/US2002/036681
Other languages
French (fr)
Other versions
WO2003041656A2 (en
Inventor
Victoria Rogers
Philippe J M Dor
Joseph A Fix
Hiroyuki Kojima
Kazuhiro Sako
Original Assignee
Yamanouchi Pharma Tech Inc
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Tech Inc, Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Tech Inc
Priority to JP2003543543A priority Critical patent/JP4882200B2/en
Priority to KR1020107024523A priority patent/KR101132969B1/en
Priority to MXPA04004544A priority patent/MXPA04004544A/en
Priority to EP02782303A priority patent/EP1443901A4/en
Priority to CA2466657A priority patent/CA2466657C/en
Priority to AU2002348279A priority patent/AU2002348279C1/en
Publication of WO2003041656A2 publication Critical patent/WO2003041656A2/en
Publication of WO2003041656A3 publication Critical patent/WO2003041656A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to novel oral sustained-release formulations for delivery of an active agent (e.g., a drug), especially a highly water soluble drug. More particularly, this invention relates to novel formulations comprising a micelle-forming drug having a charge and at least one polymer having an opposite charge. Methods of using the novel formulations are also provided.
PCT/US2002/036681 2001-11-13 2002-11-12 Soluble drug extended release system WO2003041656A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2003543543A JP4882200B2 (en) 2001-11-13 2002-11-12 Water-soluble drug sustained release technology
KR1020107024523A KR101132969B1 (en) 2001-11-13 2002-11-12 Soluble drug extended release system
MXPA04004544A MXPA04004544A (en) 2001-11-13 2002-11-12 Soluble drug extended release system.
EP02782303A EP1443901A4 (en) 2001-11-13 2002-11-12 Soluble drug extended release system
CA2466657A CA2466657C (en) 2001-11-13 2002-11-12 Soluble drug extended release system
AU2002348279A AU2002348279C1 (en) 2001-11-13 2002-11-12 Soluble drug extended release system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US787701A 2001-11-13 2001-11-13
US10/007,877 2001-11-13

Publications (2)

Publication Number Publication Date
WO2003041656A2 WO2003041656A2 (en) 2003-05-22
WO2003041656A3 true WO2003041656A3 (en) 2003-10-23

Family

ID=21728577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036681 WO2003041656A2 (en) 2001-11-13 2002-11-12 Soluble drug extended release system

Country Status (10)

Country Link
EP (1) EP1443901A4 (en)
JP (2) JP4882200B2 (en)
KR (2) KR101132969B1 (en)
CN (1) CN100534531C (en)
AU (1) AU2002348279C1 (en)
CA (1) CA2466657C (en)
MX (1) MXPA04004544A (en)
PL (1) PL374280A1 (en)
RU (1) RU2322263C2 (en)
WO (1) WO2003041656A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
JP4822092B2 (en) * 2003-09-01 2011-11-24 大正製薬株式会社 W / O / W type composite emulsion
US20060210625A1 (en) * 2003-11-04 2006-09-21 Shire Laboratories, Inc. Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
KR100638041B1 (en) * 2003-12-24 2006-10-23 주식회사 삼양사 A nanoparticle composition of a water-soluble drug for oral administration and a preparation method thereof
AU2010228258A1 (en) * 2009-03-25 2011-09-29 Aska Pharmaceutical Co., Ltd. Solid preparation
KR101319420B1 (en) * 2011-03-18 2013-10-17 한남대학교 산학협력단 Water-soluble positive-charged drug delivery system with sustained release behavior
JP5992504B2 (en) * 2011-04-11 2016-09-14 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ Surface-induced degradation of nanocontainers
CN102977413B (en) * 2011-09-07 2015-05-13 江南大学 New method for preparing micelles by compounding polymers
CN103083222B (en) * 2011-10-28 2015-08-19 江南大学 One kettle way prepares three-component polymer micelle
JP6041823B2 (en) 2013-03-16 2016-12-14 ファイザー・インク Tofacitinib oral sustained release dosage form
KR20220022829A (en) * 2020-08-19 2022-02-28 주식회사 모든바이오 A nanoparticle containing glycyrrhizin and water-soluble drug, pharmaceutical composition containing the thereof, and method for preparing the thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32806B1 (en) * 1968-05-21 1973-12-12 American Home Prod Sustained release drug composition
JPS6410466A (en) * 1987-07-01 1989-01-13 Brother Ind Ltd Data recording and reproducing method for magnetic disk
ES2179829T3 (en) * 1992-09-18 2003-02-01 Yamanouchi Pharma Co Ltd PREPARATION OF HYDROGEL OF PROLONGED RELEASE.
US6221399B1 (en) * 1995-08-17 2001-04-24 Csir Method of making controlled release particles of complexed polymers
IT1297461B1 (en) * 1997-10-29 1999-12-17 Ciocca Maurizio PREPARATION OF CONTROLLED RELEASE TABLETS BASED ON COMPLEXES BETWEEN CARRAGENANO AND SOLUBLE BASIC DRUGS
ID29843A (en) * 1998-09-14 2001-10-18 Ranbaxy Lab Ltd DRUG GIVING SYSTEM THROUGH THE REGULAR CONTROL OF THE MOUTH WHICH PROVIDES CONTROL AND TEMPORARY ACTIVITIES
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (en) * 2001-06-21 2004-02-25 Astrazeneca Ab PHARMACEUTICAL FORMULATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1443901A4 *

Also Published As

Publication number Publication date
JP4882200B2 (en) 2012-02-22
KR20050044424A (en) 2005-05-12
MXPA04004544A (en) 2005-03-31
JP4894958B2 (en) 2012-03-14
KR101132969B1 (en) 2012-04-09
EP1443901A2 (en) 2004-08-11
JP2005508995A (en) 2005-04-07
KR101016619B1 (en) 2011-02-23
CA2466657C (en) 2011-02-01
RU2004117848A (en) 2005-05-27
CA2466657A1 (en) 2003-05-22
AU2002348279C1 (en) 2008-09-04
RU2322263C2 (en) 2008-04-20
CN1612726A (en) 2005-05-04
CN100534531C (en) 2009-09-02
KR20100123779A (en) 2010-11-24
PL374280A1 (en) 2005-10-03
AU2002348279B2 (en) 2008-01-24
JP2011068700A (en) 2011-04-07
EP1443901A4 (en) 2010-06-16
WO2003041656A2 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
WO2002045754A3 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
MXPA03007215A (en) Pharmaceutical formulations.
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
AU2001283359A1 (en) Drug release (delivery system)
ZA200200743B (en) Preserved pharmaceutical formulations.
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
WO2003000018A3 (en) Dopamine agonist formulations for enhanced central nervous system delivery
WO2006084164A8 (en) Gastric retention and controlled release delivery system
WO2004016248A8 (en) Galenic formulation for colon targeted delivery of active principles
IL161857A0 (en) Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
BG108516A (en) Pharmaceutical formulation
WO2003041656A3 (en) Soluble drug extended release system
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
WO2002015959A3 (en) Compounds and compositions for delivering active agents
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
WO2005039481A3 (en) Oral drug delivery system
WO2005034999A3 (en) Composition comprising association complex of a pharmaceutical and a poloxamer
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
AU6386801A (en) System for the release of active ingredients
WO2005051350A3 (en) Water dispersible tablet
ZA200402729B (en) Pharmaceutical formulation comprising (R) -bicalutamide.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 00582/KOLNP/2004

Country of ref document: IN

Ref document number: 582/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2466657

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002782303

Country of ref document: EP

Ref document number: 2002348279

Country of ref document: AU

Ref document number: 1020047007206

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003543543

Country of ref document: JP

Ref document number: 374280

Country of ref document: PL

Ref document number: PA/a/2004/004544

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 20028270355

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002782303

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002348279

Country of ref document: AU

Date of ref document: 20021112

Kind code of ref document: B

WWE Wipo information: entry into national phase

Ref document number: 1020107024523

Country of ref document: KR